Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermezzo for middle-of-the-night insomnia
NCT00380081Phase 3Completed
- Sponsor
- Transcept Pharmaceuticals
- Start
- Apr 2006
- Primary completion
- Jul 2006
01
Overview
Phase 3, randomised, double-blind trial of zolpidem sublingual tablet in Insomnia (6 arms), sponsored by Transcept Pharmaceuticals. Primary endpoint: Latency to Persistent Sleep at 2 days. Started Apr 2006; status: completed.
02
Drugs
zolpidem sublingual tablet
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT00380081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00380081.